Loading
companiesCompany
Nanobiotix
Nanobiotix is the Paris nanomedicine company behind NBTXR3, hafnium oxide nanoparticles injected into a tumour to make radiotherapy deposit more energy inside it.
Overview
Founded in 2003 and listed on Euronext Paris and Nasdaq, Nanobiotix built its business on the physics of radioenhancement: high atomic number nanoparticles that absorb X-rays and amplify the dose within the tumour. Its lead product NBTXR3 received a European CE mark for soft-tissue sarcoma in 2019 and is in the NANORAY-312 phase 3 trial in head and neck cancer, licensed to Johnson and Johnson in 2023.
Headquarters
Paris, France, FR
Scorecard
All companies#326of 1244 companies, score 12
- phase 3 +3
- modalities +2
- regions +1
- registry trials +6
0 approved, 1 in phase 3, 0 earlier, 0 targets, 10 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
2003
Phase 3Hafnium oxide nanoparticle radioenhancer, injected into the tumour
NBTXR3 is Nanobiotix's radioenhancer: a single injection of hafnium oxide nanoparticles that makes ordinary radiotherapy hit harder inside the tumour. It carries a European CE mark for soft-tissue sarcoma and is in a phase 3 trial in head and neck cancer with Johnson and Johnson.
Similar pages
- TreatmentNimorazole
Shares Radiosensitisers, Head and neck squamous cell carcinoma and the tag radiation-wave3.
- TreatmentEvofosfamide
Shares Sarcomas (soft tissue, bone, GIST) and the tag radiation-wave3.
- TreatmentAvasopasem manganese
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
- TreatmentPilocarpine
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
- PersonSylvie Bonvalot
Shares Act.In.Sarc, NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial, Sarcomas (soft tissue, bone, GIST).
- TreatmentJNJ-90301900
Shares NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer, Head and neck squamous cell carcinoma.
- TrialBonner trial (cetuximab plus radiotherapy)
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
- TrialRTOG 91-11
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
cancers
technologies
drugs
Phase 3Hafnium oxide nanoparticle radioenhancer, injected into the tumour